Monograph Details
|
|
Central Nervous System
> Mood disorders
|
|
CELEXA ORAL SOLUTION |
| Manufacturer |
|
Forest Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
SSRI. |
| Generic Name |
|
Citalopram (as HBr) 2mg/mL; sugar- and alcohol-free; peppermint flavor; contains parabens. |
| Also |
|
• CELEXA
|
| Indications |
|
Depression. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 20mg once daily; after ≥1 week may increase to 40mg once daily; may then increase to 60mg once daily for non-responders or partial responders. Elderly or hepatic impairment: 20mg once daily; may increase to 40mg once daily for nonresponders. |
| Contraindications |
|
During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of citalopram. |
| Precautions |
|
History of seizures or mania/hypomania. Hepatic or severe renal impairment (CrCl <20mL/min). Altered metabolic or hemodynamic states. Recent MI. Unstable heart disease. Suicidal tendencies. ECT. Avoid abrupt cessation. Reevaluate periodically. Write Rx for smallest practical amount. Labor & delivery. Pregnancy (Cat.C) (avoid 3rd trimester; see literature for effects on neonate). Nursing mothers: not recommended. |
| Interactions |
|
MAOIs: see Contraindications. Do not give with escitalopram. May be potentiated by cimetidine, potent inhibitors of CYP3A4 (eg, azole antifungals, macrolides), or potent inhibitors of CYP2C19 (eg, omeprazole). May be antagonized by carbamazepine. Caution with tricyclic antidepressants, lithium, other centrally-acting drugs, oral anticoagulants, NSAIDs, aspirin. Alcohol: not recommended. Increases metoprolol levels. Weakness, hyperreflexia, incoordination with 5-HT1B/1D agonists (eg, sumatriptan). |
| Adverse Reactions |
|
GI upset, dry mouth, somnolence, insomnia, increased sweating, anorexia, rhinitis, sexual dysfunction, agitation, fatigue, arthralgia, myalgia, hyponatremia, SIADH, abnormal bleeding. |
| How Supplied |
Tabs—100
Soln—240mL |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
